Cytokinetics, Inc. : Cytokinetics to Announce Second Quarter Results on July 31, 2013

 Cytokinetics, Inc. : Cytokinetics to Announce Second Quarter Results on July
                                   31, 2013

South San Francisco, CA., July 18, 2013, - Cytokinetics, Incorporated (Nasdaq:
CYTK) announced today that it is scheduled to report second quarter results on
Wednesday, July 31, 2013 at 4:00 PM Eastern Time. Following the announcement,
Cytokinetics' senior management will host a conference call at 4:30 PM Eastern
Time to discuss operational and financial results and the company's outlook
for the future.

The conference call will  be simultaneously webcast and  can be accessed  from 
the homepage and in the Investor Relations section of Cytokinetics' website at
www.cytokinetics.com. The  live  audio of  the  conference call  can  also  be 
accessed by telephone by dialing  either (866) 999-CYTK (2985) (United  States 
and Canada)  or (706)  679-3078  (international) and  typing in  the  passcode 
92572524.

An archived replay of the webcast will be available via Cytokinetics'  website 
until August 7,  2013. The  replay will also  be available  via telephone  by 
dialing  (855)  859-2056  (United  States   and  Canada)  or  (404)   537-3406 
(international) and typing in the passcode  92572524 July 31, 2013 at 5:30  PM 
Eastern Time until August 7, 2013.

About Cytokinetics

Cytokinetics is  a clinical-stage  biopharmaceutical  company focused  on  the 
discovery and development of novel  small molecule therapeutics that  modulate 
muscle function for the  potential treatment of  serious diseases and  medical 
conditions.  Cytokinetics'  lead  drug  candidate  from  its  cardiac   muscle 
contractility program, omecamtiv mecarbil, is in Phase II clinical development
for the potential treatment  of heart failure. Amgen  Inc. holds an  exclusive 
license worldwide to develop and commercialize omecamtiv mecarbil and  related 
compounds,   subject    to    Cytokinetics'    specified    development    and 
commercialization  participation   rights.   Cytokinetics   is   independently 
developing tirasemtiv,  a  fast  skeletal muscle  activator,  as  a  potential 
treatment for diseases  and medical conditions  associated with  neuromuscular 
dysfunction. Tirasemtiv is currently the subject of a Phase II clinical trials
program and has been granted orphan drug designation and fast track status  by 
the U.S. Food and Drug Administration and orphan medicinal product designation
by the European Medicines  Agency for the  potential treatment of  amyotrophic 
lateral sclerosis, a debilitating disease of neuromuscular impairment in which
treatment   with   tirasemtiv   produced   potentially   clinically   relevant 
pharmacodynamic effects  in Phase  II trials.  Cytokinetics is  collaborating 
with Astellas Pharma Inc. to  develop CK-2127107, a skeletal muscle  activator 
structurally distinct from tirasemtiv, for non-neuromuscular indications. All
of these drug candidates have arisen from Cytokinetics' muscle biology focused
research  activities   and  are   directed  towards   the  cytoskeleton.   The 
cytoskeleton is a complex biological  infrastructure that plays a  fundamental 
role within every human cell. Additional information about Cytokinetics can be
obtained at www.cytokinetics.com.

This press release  contains forward-looking  statements for  purposes of  the 
Private Securities Litigation  Reform Act  of 1995  (the "Act").  Cytokinetics 
disclaims any intent or obligation to update these forward-looking statements,
and claims  the  protection  of  the Act's  safe  harbor  for  forward-looking 
statements. Examples  of such  statements  include, but  are not  limited  to, 
statements relating to planned presentations, and the properties and potential
benefits of Cytokinetics' drug candidates and potential drug candidates.  Such 
statements are based on management's current expectations, but actual  results 
may differ materially due to  various risks and uncertainties, including,  but 
not limited to, potential difficulties or delays in the development,  testing, 
regulatory approval  and  production  of  Cytokinetics'  drug  candidates  and 
potential drug candidates that could  slow or prevent clinical development  or 
product approval, including risks  that current and  past results of  clinical 
trials or preclinical studies may not be indicative of future clinical  trials 
results and that Cytokinetics' drug  candidates and potential drug  candidates 
may have unexpected adverse side  effects or inadequate therapeutic  efficacy. 
For  further  information   regarding  these  and   other  risks  related   to 
Cytokinetics' business, investors  should consult  Cytokinetics' filings  with 
the Securities and Exchange Commission.



Cytokinetics, Incorporated:      
Joanna L. Goldstein   
Manager, Corporate Communications and Marketing
(650) 624-3000

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: Cytokinetics, Inc. via Thomson Reuters ONE
HUG#1717549
 
Press spacebar to pause and continue. Press esc to stop.